University of Texas, Arlington NURS 5334/NURS5334: Quiz 2 40 Questions and Answers (explained) | 100% correct 2025/26.

NURS 5334/NURS5334
b5 Stuvia: the best study material from your fellow students
b5 b5 b5 b5 b5 b5 b5 b5




University of Texas, Arlington NURS 5334/NURS5334: Quiz 2 b5 b5 b5 b5 b5 b5 b5




40 Questions and Answers (explained) | 100% correct
b5 b5 b5 b5 b5 b5 b5 b5




2025/26. b5




Section 1: Pharmacokinetics & Pharmacodynamics
b5 b5 b5 b5




(Questions 1–12)
b5 b5




1. A patient with end-stage renal disease (eGFR <15 mL/min) is prescribed a
b5 b5 b5 b5 b5 b5 b5 b5 b5 b5 b5




medication that is 70% renally excreted. The nurse practitioner should anticipate:
b5 b5 b5 b5 b 5 b5 b5 b5 b5 b 5 b5




A. Increasing the dose by 50% b5 b5 b5 b5




B. Decreasing the dosing frequency b 5 b5 b 5




C. Changing to a prodrug b5 b5 b5




D. Adding a diuretic to enhance excretion
b5 b5 b5 b5 b5




Answer: B — Reduced renal clearance leads to drug accumulation. Decreasing
b5 b5 b5 b5 b5 b5 b5 b5 b5 b5




frequency maintains therapeutic levels without toxicity .
b5 b5 b5 b5 b5 b5 b5




2. Which cytochrome P450 enzyme is most commonly involved in clinically
b5 b5 b5 b5 b5 b5 b5 b5 b5




significant drug-drug interactions?
b5 b5 b5




A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C9

Answer: C — CYP3A4 metabolizes approximately 50% of marketed drugs and is highly
b5 b5 b5 b5 b5 b5 b5 b5 b5 b5 b5 b5




susceptible to inhibition and induction .
b5 b5 b5 b5 b5 b5

, NURS 5334/NURS5334
b5 Stuvia: the best study material from your fellow students
b5 b5 b5 b5 b5 b5 b5 b5




3. A drug with high first-pass effect is given orally. The NP understands that:
b5 b5 b5 b5 b5 b5 b5 b5 b5 b5 b5 b5




A. The drug will have increased bioavailability
b5 b5 b5 b5 b5




B. The drug must be given via a non-oral route to avoid extensive hepatic metabolism
b5 b5 b5 b5 b5 b5 b5 b5 b5 b5 b5 b5 b5




C. Gastric pH will alter absorption significantly
b5 b5 b5 b5 b5




D. Protein binding will be decreasedb5 b5 b5 b5




Answer: B — High first-pass effect means the liver metabolizes much of the drug
b5 b5 b5 b5 b5 b5 b5 b5 b5 b5 b5 b5 b5




before it reaches systemic circulation .
b5 b5 b5 b5 b5 b5




4. A patient takes warfarin. Starting rifampin (a potent CYP inducer) will likely:
b5 b5 b5 b5 b5 b5 b5 b5 b5 b5 b5




A. Increase INR and bleeding risk b5 b5 b5 b5




B. Decrease INR and reduce anticoagulant effect b5 b 5 b 5 b5 b 5




C. Have no effect on INR
b5 b5 b5 b5




D. Cause warfarin toxicityb5 b 5




Answer: B — Rifampin induces CYP enzymes that metabolize warfarin, reducing its
b5 b5 b5 b5 b5 b5 b5 b5 b5 b5 b5




anticoagulant effect .
b5 b5 b5




5. What is the study of drug movement throughout the body called?
b5 b5 b5 b5 b5 b5 b5 b5 b5 b5




A. Pharmacodynamics
B. Pharmacokinetics
C. Pharmacotherapeutics
D. Pharmacogenomics

Answer: B — Pharmacokinetics encompasses absorption, distribution, metabolism, and
b5 b5 b5 b5 b5 b5 b5 b5




excretion (ADME) .
b5 b5 b5




6. A patient with liver cirrhosis has reduced synthesis of albumin. The NP should
b5 b5 b5 b5 b5 b5 b5 b5 b5 b5 b5 b5




anticipate that a highly protein-bound drug will have:
b5 b5 b5 b5 b5 b5 b5 b5